Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of rituximab (RTX) [Roche] to submit evidence for the clinical and cost effectiveness of RTX as first-line maintenance treatment for patients with follicular non-Hodgkin’s lymphoma (fNHL) whose disease has resp...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Greenhalgh, Janette, Bagust, Adrian, Boland, Angela, Blundell, Michaela, Oyee, James, Beale, Sophie, Dundar, Yenal, Hockenhull, Juliet, Proudlove, Chris, Chu, Patrick
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer International Publishing AG 2013
Onderwerpen:
Review Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3654180/
https://ncbi.nlm.nih.gov/pubmed/23576017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-013-0043-8
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items